Regeneron and Sanofi announce positive phase 2 top-line dupilumab results
Regeneron and Sanofi announced a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with CSwNP. September 30, 2014